Table 3 Comparison of quality-of-life (QoL) scores, as measured by EORTC-QLQ-C30, before the first cycle of gemcitabine and after the second cycle (the first to be administered at home) (N=16)
Baseline: mean | Cycle 2: mean | Mean difference | Wilcoxon P | |
|---|---|---|---|---|
Functional scales a | ||||
Physical functioning | 60.9 | 52.5 | 8.44 | 0.65 |
Role functioning | 57.3 | 38.5 | 18.8 | 0.01 |
Emotional functioning | 65.4 | 61.8 | 3.68 | 0.22 |
Cognitive functioning | 87.1 | 74.9 | 12.2 | 0.10 |
Social functioning | 71.8 | 55.2 | 16.6 | 0.066 |
Global health status/QoL (QL2)a | 62.8 | 52.9 | 9.93 | 0.062 |
Symptom scales/items b | ||||
Fatigue | 32.3 | 49.3 | −16.9 | 0.02 |
Nausea and vomiting | 14.6 | 32.2 | −17.7 | 0.02 |
Pain | 17.6 | 23.9 | −6.31 | 0.61 |
Dyspnoea | 49.7 | 49.7 | 0.00 | 0.81 |
Insomnia | 28.9 | 24.8 | 4.12 | 0.75 |
Appetite loss | 28.9 | 51.9 | −23.0 | 0.08 |
Constipation | 16.6 | 37.2 | −20.7 | 0.053 |
Diarrhoea | 0 | 6.6 | −6.60 | 0.08 |
Financial difficulties | 22.7 | 16.5 | 6.25 | 0.16 |
